Navigation Links
Former Manchester City Lord Mayor Has Hope Restored at New Beike Stem Cell Facility

QINGDAO, China, Feb. 14 /Xinhua-PRNewswire/ -- Shenzhen Beike Biotechnology Co., Ltd. ( ), the world leader in the use of umbilical cord stem cells to successfully treat a variety of illnesses, announced that Audrey Jones, the former Lord Mayor of Manchester, has returned today to the United Kingdom (UK) with significant improvement in her debilitating and life-threatening condition known as cerebellar atrophy. As the latest of the over 2500 patients Beike has treated to date, the former Lord Mayor's improvements in China have made her a strong advocate for stem cell applications and the treatments that Beike Biotech provides. Before becoming the first patient in Beike's brand new stem cell treatment facility in the eastern China seaport of Qingdao, Lord Mayor Jones' neurosurgeon specialist in the UK told her there was no treatment for her condition, no cure, and that she would increasingly lose control of her body movements and functions until she was dead within a few years. After an intensive five week combination stem cell and therapy treatment program at Beike, Audrey Jones left China with much greater strength, improved balance, and more endurance, allowing her to walk normally without a wheelchair for the first time in years. Upon arrival in the UK today, she walked off the plane under her own power into the arms of her waiting family. More details on former Lord Mayor of Manchester Audrey Jones and her significant improvements can be found on China's leading stem cell news website, China Stem Cell News ( ).

"In England, I was looking into a bleak future. I had lost all hope and was deeply depressed. When I heard about Beike and the ability to receive stem cells right away, I began to hope again, which means everything," said Audrey Jones. "After going through the full program, seeing my own improvement, and walking again, my hope has been restored. Now my whole life is ahead of me," she stated.

Audrey Jones was Manchester's first Liberal Democrat Lord Mayor from May 2003 to June 2004, and is now a Councillor in the Town Hall of Manchester city, where she was born, educated, and has lived all her life. Before her position as Lord Mayor, Audrey Jones was part owner and Director of the South Manchester Reporter newspaper, also authoring a book on the City's children during World War II entitled, "Farewell Manchester." Before coming to China, she had been using an electric wheelchair to get around Town Hall, needed to be carried up and down stairs by others, and had suffered from daily bouts of debilitating fatigue.

"I can't wait to just walk right in the door of Town Hall and prove to others that there really is hope out there," said Audrey Jones. "Some people think that China couldn't possibly be a leader in advanced medical treatments like stem cells, but it is. My specialist and others who don't understand how advanced China has become told me that it must be a scam, and to be careful because China is a backward country. After coming here, I realize that to think of China as backward betrays an incredible ignorance," said former Lord Mayor Jones.

Audrey Jones was treated at Beike Biotech's stem cell treatment center in Qingdao, the newest of four world-class Beike hospital facilities located in major cities across China. Qingdao is world famous as the home of Tsing-Tao beer and is the city where the 2008 Olympic Sailing Competition is to be held later this year. The new Qingdao facility can accommodate up to 30 patients with their families and boasts state-of-the-art therapy equipment with a highly trained nursing staff as well as a groundbreaking global medical team. It provides quality stem cells to patients through intravenous (IV) drip, direct injection into the spinal canal via lumbar puncture, as well as surgery whereby stem cells are directly applied to injured sections of the spinal cord.

"With such growing demand and rapid increase in patients coming to China for Beike stem cells, our newest facility in Qingdao comes just in time to help those that do not want to wait," said Dr. Sean Hu, Chairman of Beike Biotechnology Co., Ltd. "I am elated to have former Lord Mayor of Manchester as our first patient in Qingdao, and even more pleased to see her excellent improvement from our holistic treatment. Beike patients represent people of the highest integrity from all over the world and I am glad to see all of them receiving benefit from our stem cell treatments," he said.

About Beike Biotechnology Company Limited

Beike is a biotechnology company that was founded in July 2005 with capital from Beijing University, Hong Kong University of Science and Technology and Shenzhen City Hall when it commercialized stem cell technology that had been in research since 1999. As a private high-tech enterprise, it is dedicated to the clinical application of stem cell research. It is also supported with funds from the China State National Fund. The research and clinical work is a collaboration of Beijing University, Hong Kong University of Science and Technology, No. 3 Army Medical University, Zhongshan Medical University, Guiyang Medical College and Zhengzhou University.

For more information, please contact:

Kirshner Ross-Vaden,

VP -- Foreign Patient Relations,

Beike Biotechnology Company, Ltd.

Tel: +1-877-278-3623



SOURCE Shenzhen Beike Biotechnology Co., Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion
2. Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer
3. Former Patent Office Solicitor and Judge Joins Rothwell Figg
4. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
7. David Barker, Former Illumina CSO, Joins GenVaults Scientific Advisory Board
8. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
9. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
10. Stem Cell Leader Beike Biotech and Chinas Tsinghua University Receive US$4 Million for Stem Cell Reprogramming Laboratory
11. Tasker Products Installs Scalder Application at New Poultry Processors Facility
Post Your Comments:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):